Back to Articles

Semax: The Russian Nootropic Peptide Now Under FDA Review

April 29, 20265 min readTruPeptide Editorial

What Is Semax?

Semax is a synthetic heptapeptide — seven amino acids (Met-Glu-His-Phe-Pro-Gly-Pro) — developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. It's an analog of ACTH(4-10), a fragment of adrenocorticotropic hormone, but without ACTH's hormonal effects on cortisol.

In Russia, Semax has been approved as a prescription drug since 2011 for:

  • Cerebral ischemia (stroke recovery)
  • Cognitive impairment
  • Optic nerve atrophy
  • Peptic ulcer disease (as an adjunct)

It's administered as a nasal spray — no injections required — which makes it unusually accessible for a peptide.

How It Works

Semax's mechanism is multifaceted, which is part of what makes it interesting and part of what makes it hard to study in the Western clinical trial framework:

BDNF upregulation: Semax increases expression of Brain-Derived Neurotrophic Factor and its receptor TrkB in the hippocampus. BDNF is often called "fertilizer for the brain" — it promotes neuronal survival, synaptic plasticity, and the formation of new neural connections.

Neurotransmitter modulation: Affects serotonergic, dopaminergic, and adrenergic systems. This likely accounts for its reported effects on mood, focus, and motivation.

Anti-inflammatory: Reduces neuroinflammation through modulation of inflammatory cytokines. This is relevant for both acute brain injury (stroke) and chronic neurodegeneration.

Neuroprotection: Reduces oxidative stress in neural tissue. Animal studies show significant protection against ischemic brain damage when administered before or shortly after the event.

The Evidence — What We Know and Don't Know

What the Russian clinical data shows:

  • Improved cognitive outcomes in stroke patients (multiple clinical studies)
  • Reduced anxiety and improved focus in patients with cognitive impairment
  • Favorable safety profile across decades of clinical use
  • Effective as a nasal spray with good bioavailability

What's missing for Western regulators:

  • No Phase 1-3 clinical trials conducted under FDA IND
  • Most published research is from Russian institutions with limited independent replication
  • Study designs don't always meet Western standards for randomization and blinding
  • Long-term safety data exists but primarily in Russian medical literature

This is the core tension in Semax's regulatory story. There's substantial clinical experience — millions of prescriptions in Russia — but the evidence base doesn't fit neatly into the FDA's approval framework.

The Regulatory Path: PCAC July 24, 2026

Semax is one of seven peptides scheduled for review at the FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026. Specifically, Semax is on the Day 2 agenda (July 24) alongside Emideltide and Epitalon.

Here's the timeline:

  • September 2023: FDA places Semax on Category 2 restricted list
  • April 15, 2026: FDA announces Semax will be removed from Category 2
  • April 22, 2026: Removal effective — Semax enters regulatory gray zone
  • July 24, 2026: PCAC reviews Semax for potential addition to 503A bulks list

If PCAC recommends adding Semax to the 503A list, licensed compounding pharmacies could legally prepare it with a physician prescription. If PCAC votes against it, Semax would likely return to a restricted status.

The challenge for Semax at PCAC is the limited Western clinical data. The committee may view the Russian evidence as insufficient, or they may recognize the decades of clinical use as meaningful real-world evidence. The outcome is genuinely uncertain.

How People Currently Access Semax

In Russia: Available as a prescription nasal spray (brand name Semax) at pharmacies. No special access required.

In the US (current): Available from research peptide suppliers as a research chemical. Not for human use. Some nootropic-focused vendors (like Limitless Life Nootropics) are particularly well-regarded for Semax quality. A few telehealth clinics have offered it in the post-April 2026 gray zone, but this is legally ambiguous.

After PCAC (if approved): Would be available through licensed 503A compounding pharmacies with a physician prescription, likely as a nasal spray formulation.

Common Protocols (Educational Reference)

The most common form is an intranasal spray, typically delivering 100 mcg per spray:

  • Cognitive enhancement: 200-600 mcg daily (2-6 sprays), divided into 1-2 doses
  • Cycle length: 2-4 weeks on, 1-2 weeks off
  • Timing: Morning or early afternoon (can be stimulating)
  • Stacking: Often combined with Selank (a related anxiolytic peptide) for balanced cognitive enhancement

Protocol information is for educational reference only. Dosing varies by individual and should be guided by a licensed healthcare provider.

The Bigger Picture

Semax represents a broader question facing the FDA: how should the US regulatory system handle compounds with extensive international clinical use but limited US-specific trial data? This isn't unique to Semax — Thymosin Alpha-1 (approved in 35+ countries), Cerebrolysin (approved in many European and Asian countries), and several other peptides face the same challenge.

The PCAC's decision on Semax will set a precedent for how the FDA weighs international clinical experience against its traditional requirement for US-based clinical trials.

Semax is scheduled for PCAC review on July 24, 2026. For live updates, see our FDA Status Tracker. For the full compound profile, see Semax.